ABSTRACT
La histiocitosis de células de Langerhans (HCL) es una enfermedad caracterizada por la proliferación de células dendríticas CD1a+con compromiso orgánico único o difuso. La identificación de mutaciones génicas recurrentes ha confirmado la hipótesis de HCL como una verdadera neoplasia. La papulosis linfomatoide (PL) pertenece al espectro de los linfomas cutáneos primarios CD30+. La HCL ha sido descrita en asociación con otros trastornos linfoproliferativos, pero hasta la fecha, las lesiones constituidas por células de Langerhans (CL) han sido consideradas de carácter reactivo, relacionada con citocinas producidas por la interacción linfoma microambiente. Algunos autores designan estas lesiones «Langerhans cells like lesions». Presentamos el caso de una mujer de 28 años con HCL multisistémica y presencia simultánea de lesiones de PL con hiperplasia reactiva de CL
Langerhans cell histiocytosis (LCH) is a disease characterized by proliferation of CD1a+dendritic cells with local or diffuse organ compromise. The identification of recurrent gene mutations has confirmed the hypothesis of LCH as a true neoplasm. Lymphomatoid papulosis (LyP) belongs to the spectrum of CD30+primary cutaneous lymphomas. LCH has been described in association with other lymphoproliferative disorders. However, lesions constituted by Langerhans cells (LC) have been commonly considered reactive, related to cytokines produced by the lymphoma-microenvironment interaction. Some authors designate these lesions as "Langerhans cells-like lesions". We present the case of a 28-years-old woman with multisystem LCH and simultaneous PyL lesions with reactive LC hyperplasia
Subject(s)
Humans , Female , Adult , Histiocytosis, Langerhans-Cell/pathology , Lymphomatoid Papulosis/pathology , Dendritic Cells/pathology , Lymphoproliferative Disorders/pathology , Prednisone/therapeutic use , Cladribine/therapeutic useABSTRACT
This study was aimed at determining whether dienestrol (DIES) affects reproduction in male offspring of rats following oral maternal exposure during gestation and lactation. Pregnant rats were treated from GD 6 to PND 21. Animals received 0 (control-vehicle), 0.75, 1.5, 3.12, 6.25, 12.5, 50, 75⯵g/kgâ¯bw/d of DIES. A control group -without vehicle-was also included. High DIES concentrations caused abortions at 75 and 50⯵g/kgâ¯bw/d, while at 12.5⯵g/kgâ¯bw/d had still miscarriages. Ten male rats per group were kept alive until PND 90 to ensure sexual maturity. Body and organ weights, anogenital distance (AGD) at PNDs 21 and 90, biochemical and sperm parameters like motility, viability, morphology, spermatozoa and resistant spermatid counts, and histopathology for sexual organs and liver were determined. An increase in organ weight (liver and sexual organs) and a decrease in AGD due to vehicle were found. A reduction of sperm motility and viability, and an increase of abnormal sperm morphology were caused by DIES, which provoked a dose-dependent prostatitis. Maternal exposure to DIES induced toxicity on the reproductive system of the male offspring, which could affect the capacity of fertilization.
Subject(s)
Dienestrol/toxicity , Estrogens, Non-Steroidal/toxicity , Genitalia, Male/drug effects , Maternal Exposure , Sperm Motility/drug effects , Spermatozoa/drug effects , Abortion, Veterinary/chemically induced , Administration, Oral , Animals , Body Weight/drug effects , Dienestrol/administration & dosage , Dose-Response Relationship, Drug , Estrogens, Non-Steroidal/administration & dosage , Female , Male , Organ Size/drug effects , Pregnancy , Prostatitis/chemically induced , Rats , Sperm CountABSTRACT
Langerhans cell histiocytosis (LCH) is a disease characterized by proliferation of CD1a+dendritic cells with local or diffuse organ compromise. The identification of recurrent gene mutations has confirmed the hypothesis of LCH as a true neoplasm. Lymphomatoid papulosis (LyP) belongs to the spectrum of CD30+primary cutaneous lymphomas. LCH has been described in association with other lymphoproliferative disorders. However, lesions constituted by Langerhans cells (LC) have been commonly considered reactive, related to cytokines produced by the lymphoma-microenvironment interaction. Some authors designate these lesions as "Langerhans cells-like lesions". We present the case of a 28-years-old woman with multisystem LCH and simultaneous PyL lesions with reactive LC hyperplasia.
Subject(s)
Histiocytosis, Langerhans-Cell/complications , Lymphomatoid Papulosis/complications , Adult , Female , HumansABSTRACT
BACKGROUND: Gastrointestinal stromal tumors are sarcomas of the digestive tract characterized by mutations mainly located in the c-KIT or in the platelet-derived growth factor receptor (PDGFR)-alpha genes. Mutations in the BRAF gene have also been described. Our purpose is to define the distribution of c-KIT, PDGFR and BRAF mutations in a population-based cohort of gastrointestinal stromal tumors (GIST) patients and correlate them with anatomical site, risk classification and survival. In addition, as most of the GIST patients have a long survival, second cancers are frequently diagnosed in them. We performed a second primary cancer risk assessment. METHODS: Our analysis was based on data from Tarragona and Girona Cancer Registries. We identified all GIST diagnosed from 1996 to 2006 and performed a mutational analysis of those in which paraffin-embedded tissue was obtained. Observed (OS) and relative survival (RS) were calculated according to risk classifications and mutational status. Multivariate analysis of variables for observed survival and was also done. RESULTS: A total of 132 GIST cases were found and we analyzed mutations in 108 cases. We obtained 53.7% of mutations in exon 11 and 7.4% in exon 9 of c-KIT gene; 12% in exon 18 and 1.9% in exon 12 of PDGFR gene and 25% of cases were wild type GIST. Patients with mutations in exon 11 of the c-KIT gene had a 5-year OS and RS of 59.6% and 66.3%, respectively. Patients with mutations in exon 18 of the PDGFR gene had a 5-year OS and RS of 84.6% and 89.7%. In multivariate analysis, only age and risk group achieved statistical significance for observed survival. GIST patients had an increased risk of second cancer with a hazard ratio of 2.47. CONCLUSIONS: This population-based study shows a spectrum of mutations in the c-KIT and PDGFR genes in GIST patients similar to that previously published. The OS and RS of GIST with the exon 18 PDGFR gene mutation could indicate that this subgroup of patients may be less aggressive and have a good prognosis, although less sensitive to treatment at recurrence. In our study, GIST patients have an increased risk of developing a second neoplasm.
